BioMed X Institute and Merck KGaA, Darmstadt, Germany, extend collaboration in Oncology


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Corporate News Updates; Pharma Feb 3rd 2022

German independent research institute BioMed X announces today the extension of its collaboration with Merck KGaA, Darmstadt, Germany, in the research project RNA Splicing in Cancer (RSC). As a result of the successful research work to date, Merck KGaA, Darmstadt, Germany has decided to acquire the IP rights in the project results and to continue the project for another year. The goal of the extension is to further validate novel potential drug targets based on these results.

This research program marks the partners’ fifth joint project in oncology and is already the second program to be extended beyond the originally anticipated 4-year timeframe. Since the inception of the BioMed X Institute in 2013, Merck KGaA, Darmstadt, Germany has initiated and supported a total of eight different research groups at BioMed X, also in the fields of immuno-oncology, and autoimmunity.

The RSC research program was launched at the BioMed X Institute in 2018. Emerging data indicated a critical dependency of several subtypes of cancer on a molecular mechanism called RNA splicing. The team was identifying key molecular mechanisms that generate mRNA splicing abnormalities in cancer. Such aberrant splicing can lead to constitutive activity of oncogenes, reduced expression of tumor suppressors, or drug resistance. The goal of the project was to identify novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.

“By employing omics technologies in combination with mechanistic cellular biology, we have investigated how mRNA and protein isoform expression shapes the complex pathophysiology of tumor cells. Our goal within the next year will be to identify additional cancer-specific vulnerabilities for targeted therapies based on our results”, says Dr. Alexandra Duarte who previously worked as Postdoctoral Researcher in the research group and now assumes the role of a Group Leader in the final phase of project RSC.

Dr Christian Tidona, Founder and Managing Director of the BioMed X Institute: “The continued success of our collaboration with Merck KGaA, Darmstadt, Germany demonstrates BioMed X’s growing expertise in cancer research and further deepens our trustful partnership. At the same time, the promotion of Dr. Alexandra Duarte to Group Leader in this crucial final phase of team RSC demonstrates how our innovation model is empowering the next generation of top researchers to advance their careers.”

Tags : #Biomed #Merck #Oncology #Germany

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026